Patients with muscle-invasive bladder cancer have been shown to benefit from chemotherapy prior to surgical removal of the bladder. But which type of chemotherapy leads to the best outcomes in terms of complete response rates or cancer control? Moffitt Cancer Center researchers examined data from more than 800 surgical patients with advanced bladder cancer.
Anna Giuliano, Ph.D., director of Moffitt Cancer Center’s Center for Infection Research in Cancer, delivered the opening keynote address at the 2017 European Research Organization on Genital Infection and Neoplasia (EUROGIN) International Multidisciplinary Congress. The focus of this year’s conference is human papillomavirus (HPV) and its associated cancers.